Week of Jun 6–12, 2026
Weekly GLP-1 trial and regulatory updates
Read a curated weekly view of trial changes, results, and regulatory events. Three trial drill-downs are free. Deeper trial drill-down is available with Bio1Up Plus. Prefer the newsletter format? Read GLP1 Observer ↗
This Week's Highlights
- Novo Nordisk secures UK approval for daily oral Wegovy pill↗Regulatory
- Retatrutide cuts weight 28%, plus knee OA pain and sleep apnea, in Phase 3 TRIUMPH-1↗News
- Lilly's oral orforglipron tops Novo's oral semaglutide in first head-to-head diabetes trial↗News
- Novo Nordisk's CagriSema meets primary endpoints across Phase 3 REIMAGINE trials↗News
- Boehringer's Phase 3 survodutide data reveals 63 percent liver fat reduction↗News
- AstraZeneca advances oral elecoglipron to Phase 3 following positive Phase 2b results↗News
- Pfizer's monthly berobenatide posts up to 15.9% weight loss, heads to 10 Phase 3 trials↗News
Detailed Updates
Click an NCT badge to open the trial detail drawer.approvalNovo Nordisk: Wegovy® pill (semaglutide tablets) becomes first daily GLP-1 weight-loss pill approved in the UK
Source ↗The UK's MHRA approved Novo Nordisk's daily oral Wegovy (semaglutide) for adult weight management, marking the first daily GLP-1 pill authorized for this indication in the UK market.
Phase 2ENDPOINT METBofanglutide (GZR18) US Phase 2 study (NCT06737042) met its primary endpoint in overweight and obese participants
Gan & Lee's bofanglutide injection (GZR18) met its primary endpoint in a US Phase 2 obesity trial, demonstrating 18.54% weight reduction at 52 weeks with the 48 mg dose.
Phase 3ENDPOINT METEli Lilly Presents Detailed ACHIEVE-3 Results at ADA 86th Scientific Sessions, Reinforcing Superiority of Foundayo
Detailed ACHIEVE-3 trial data presented at ADA showed Eli Lilly's oral orforglipron (Foundayo) achieved superior HbA1c reduction and weight loss compared to oral semaglutide in type 2 diabetes.
Phase 2ENDPOINT METElecoglipron (AZD5004) Phase IIb SOLSTICE trial meets primary endpoint in type 2 diabetes, detailed results presented at ADA and published in The Lancet
AstraZeneca's oral elecoglipron met the Phase 2b SOLSTICE primary endpoint, delivering a 1.9% HbA1c reduction at 26 weeks in adults with type 2 diabetes, supporting Phase 3 advancement.
Phase 2ENDPOINT METElecoglipron VISTA Phase IIb trial achieves dual primary endpoints with significant weight loss, detailed results presented at ADA and published in The Lancet
AstraZeneca's VISTA Phase 2b trial showed the 75mg dose of oral elecoglipron drove an 11.8% body weight reduction at 36 weeks in overweight or obese adults.
Phase 3ENDPOINT METDetailed results from ACHIEVE-2 trial presented at ADA 86th Scientific Sessions and published in The Lancet
Phase 3 ACHIEVE-2 results confirm Eli Lilly's Foundayo (orforglipron) provided dose-dependent, superior A1C and body weight reductions versus dapagliflozin in adults with type 2 diabetes.
Phase 3ENDPOINT METDetailed ACHIEVE-5 results presented at ADA 2026 and published in JAMA, showing superior glycemic control and weight loss with orforglipron
Detailed ACHIEVE-5 data demonstrated orforglipron superiority over placebo for HbA1c and weight reduction in type 2 diabetes patients on basal insulin, with up to 6.1% weight loss at 40 weeks.
Phase 3ENDPOINT METDetailed SYNCHRONIZE-1 results presented at ADA 2026 and published in NEJM, showing targeted visceral and liver fat reductions with survodutide
Boehringer Ingelheim's Phase 3 SYNCHRONIZE-1 MRI substudy revealed survodutide reduced visceral fat by up to 34% and liver fat by 63.1% at 76 weeks, while minimizing lean mass loss.
Phase 3Orforglipron delivers significant weight loss across all menopause stages in ATTAIN trials
New ATTAIN-1 and ATTAIN-2 data confirmed that Eli Lilly's oral orforglipron produced significant and consistent weight loss in overweight or obese women regardless of menopause stage.
Phase 3ENDPOINT METSurvodutide SYNCHRONIZE-MASLD Phase 3 trial meets co-primary endpoints, showing significant liver fat reduction and normalization
Boehringer's Phase 3 SYNCHRONIZE-MASLD trial met co-primary endpoints, showing survodutide drove significant liver fat reduction and body weight loss in adults with metabolic dysfunction-associated steatotic liver disease.
Phase 3ENDPOINT METNovo Nordisk's CagriSema REIMAGINE 1 trial demonstrates significant HbA1c and weight reductions, presented at ADA 2026 and published in The Lancet Diabetes & Endocrinology
Phase 3 REIMAGINE 1 data showed Novo Nordisk's CagriSema reduced HbA1c by 1.8% and body weight by 13.8% versus placebo in type 2 diabetes inadequately controlled on diet and exercise.
Phase 3ENDPOINT METFull REIMAGINE 2 results presented at ADA 2026 and published in The Lancet Diabetes & Endocrinology
Novo Nordisk's REIMAGINE 2 trial results confirmed CagriSema 2.4 mg/2.4 mg demonstrated superior HbA1c reductions and 14.2% weight loss compared to semaglutide alone.
Phase 3ENDPOINT METNovo Nordisk's CagriSema REIMAGINE 3 trial demonstrates significant HbA1c and weight reductions, presented at ADA 2026 and published in The Lancet
Phase 3 REIMAGINE 3 trial data revealed CagriSema reduced HbA1c by 2.33% and body weight by 12.0% in adults with type 2 diabetes on basal insulin over 40 weeks.
Phase 3ENDPOINT METLilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complications
Eli Lilly's TRANSCEND-T2D-1 trial demonstrated the triple agonist retatrutide achieved up to 2.0% A1C reduction and 16.8% weight loss at 40 weeks in adults with type 2 diabetes.
Phase 2ENDPOINT METDetailed Phase 2b VESPER-2 results presented at ADA show significant weight loss and HbA1c reduction with berobenatide in adults with obesity and type 2 diabetes
Pfizer's Phase 2b VESPER-2 study showed its weekly GLP-1 candidate berobenatide achieved up to 10.2% weight loss and 2.2% HbA1c reduction at 28 weeks in patients with obesity and diabetes.
Phase 3Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
Amgen
Status: NOT_YET_RECRUITING → RECRUITING
Phase 3A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and Obesity
Innovent Biologics (Suzhou) Co. Ltd.
Status: ACTIVE_NOT_RECRUITING → COMPLETED
Also: CompletionDateChanged (-141 days)
Phase 3A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight
Eli Lilly and Company
Status: RECRUITING → ACTIVE_NOT_RECRUITING
Phase 2A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity (SOLIS-1)
Pfizer
Status: NOT_YET_RECRUITING → RECRUITING
Phase 1A Study to Evaluate the Effect of Maridebart Cafraglutide on Insulin Sensitivity and β-cell Function in Participants With Type 2 Diabetes Mellitus
Amgen
Status: RECRUITING → ACTIVE_NOT_RECRUITING
Phase 1A Study to Investigate the Pharmacokinetics of Different Formulations and Safety of AZD5004 in Healthy Participants Aged 18 to 55 Years
AstraZeneca
Status: ACTIVE_NOT_RECRUITING → COMPLETED
Phase 1A Phase 1, Parallel, Single-Dose, Open-Label, Single-Period Study of LY3502970 in Participants With Normal Renal Function and Participants With Renal Impairment.
Eli Lilly and Company
ResultsPosted: False → True
Gan & Lee Pharmaceuticals Achieves Significant Progress in Its Dual Pipeline for Metabolic Diseases -- Weekly Insulin Ludefen (GZR4) Meets Primary Endpoint in Phase III Clinical Trial in China; Bofanglutide Meets Primary Endpoints in Phase III Weight Loss Study in China and Phase II Study in the U.S.
Source ↗Gan & Lee reported positive data for bofanglutide in US and Chinese obesity trials, and announced its once-weekly basal insulin Ludefen met primary Phase 3 endpoints in China.
People with type 2 diabetes who were increased to semaglutide 2 mg were as likely to achieve an HbA1c less than 7% and more likely to achieve greater than 5% weight loss than those who were switched to tirzepatide, in real-world data
Source ↗Retrospective data from over 64,000 patients indicates escalating to semaglutide 2 mg matches tirzepatide's blood sugar control while offering a higher likelihood of achieving 5% weight loss.
ADA: Tolerability ‘not to be underappreciated’ in Roche, Zealand’s amylin obesity prospect
Source ↗Zealand Pharma and Roche reported Phase 2 data showing their amylin analog petrelintide achieved 10.7% weight loss with superior tolerability compared to standard GLP-1s, teeing up a 2026 Phase 3 program.
ADA: Novo's Wegovy pill reaches new GLP-1 patients with impressive 3M prescription milestone
Source ↗Novo Nordisk's oral Wegovy reached 3 million U.S. prescriptions within five months, outpacing Eli Lilly's Foundayo by successfully attracting new patients to GLP-1 therapy for weight and cardiovascular management.
Also covered by: prnewswire_pharma
ADA: Kailera ‘back at work’ after record-breaking IPO with China data in hand
Source ↗Fresh off a $625 million IPO, Kailera Therapeutics presented ADA data confirming the efficacy of its Hengrui-licensed GLP-1/GIP dual agonist ribupatide in non-Asian populations.
2026 ADA | Innovent Presents Multiple Clinical and Preclinical Results of Next-Generation Obesity & Metabolic Pipeline
Source ↗Innovent Biologics advanced its oral GLP-1 pipeline, presenting Phase 1 data where its daily small molecule IBI3032 drove a 10.11% body weight reduction over 4 weeks.
ADA: Lilly posts oral semaglutide-topping data as Foundayo speeds toward 2nd potential nod in diabetes
Source ↗Buoyed by Phase 3 ACHIEVE data showing superiority over oral semaglutide, Eli Lilly plans to file Foundayo for FDA diabetes approval via a Priority Review Voucher by Q2 2026.
Also covered by: biospace
Phase 2A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity
Novo Nordisk A/S · 230 participants
Novo Nordisk registered a 230-participant Phase 2 trial to evaluate different dose escalation strategies for its investigational obesity asset NNC0662-0419.
Robust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Pfizer’s GLP-1 RA Berobenatide
Source ↗Supported by competitive weight loss and tolerability data from the Phase 2b VESPER program, Pfizer plans to advance monthly GLP-1 berobenatide into 10 Phase 3 obesity trials in 2026.
Eli Lilly's Retatrutide Shows Significant Weight Loss and Diabetes Improvements in Phase 3 TRIUMPH-1 and TRANSCEND-T2D-1 Trials
Source ↗Eli Lilly's retatrutide drove up to 28.3% weight loss in TRIUMPH-1 and 16.8% weight loss in TRANSCEND-T2D-1, alongside significant improvements in sleep apnea and osteoarthritis pain.
Novo Nordisk’s CagriSema 2.4 mg / 2.4 mg demonstrated significant reduction in HbA1c and weight across multiple studies in the REIMAGINE program presented at ADA 2026
Source ↗Novo Nordisk's CagriSema consistently outperformed semaglutide alone across the Phase 3 REIMAGINE program, achieving up to 14.2% weight loss and significant HbA1c reductions in type 2 diabetes patients.
Also covered by: fierce_biotech, stat_news
Boehringer Ingelheim’s survodutide Phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis, supporting improved metabolic health in people living with obesity
Source ↗Boehringer Ingelheim detailed Phase 3 SYNCHRONIZE data showing survodutide reduced liver fat by 63.1% and prompted the announcement of three new Phase 3b trials to expand clinical indications.
Elecoglipron, an oral small molecule GLP-1 RA, moves to Phase III programme and unlocks next chapter in AstraZeneca’s cardiometabolic and kidney portfolio
Source ↗AstraZeneca will advance oral elecoglipron into the Phase 3 EMBOLD and ELUMINATE trials after Phase 2b data showed 11.8% weight loss in obesity and 1.9% HbA1c reduction in diabetes.
Know someone who'd find this useful?